MedTrace Logo

Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients

NCT01936337 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2014-08-12

No results posted yet for this study

Summary

In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

DLX105 Hydrogel

topical administration on psoriatic plaque

DRUG

Placebo

topical administration on psoriatic plaque

Sponsors & Collaborators

  • Delenex Therapeutics AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-06-30
Completion
2014-07-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936337 on ClinicalTrials.gov